Key facts
- Active ingredient
- Sirolimus
- Drug class
- Kinase Inhibitor
- Form
- Injectable
- Strength
- Sirolimus 100MG/VIAL
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- Manufacturer
- Aadi
- What the pharmacy pays
- ~$48.61 for 30 — not your price
- FDA application
- NDA213312
Storing Fyarro, and how long it keeps
Quoted from this product’s own FDA label. Storage belongs to the product and its device, not to the drug in general — a pen and a tablet of the same medicine are kept completely differently.
- “The total maximum combined refrigerated storage time of reconstituted FYARRO in the vial and in the infusion bag is 15 hours.”
Drug class
- Kinase Inhibitor
- mTOR Inhibitor Immunosuppressant
How this class works, per Tyrosine Kinase Inhibitors - StatPearls - NCBI Bookshelf.
May treat (source: NIH RxClass)
See how Fyarro ranks — best-rated kinase inhibitor for:
Dosage forms
Injectable
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Fyarro treat?
- Fyarro (Sirolimus) may be used to treat lymphangioleiomyomatosis, perivascular epithelioid cell neoplasms, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How does Fyarro work?
- Fyarro is a kinase inhibitor. Kinase inhibitors block protein kinases, the enzymes that relay 'grow and divide' signals inside cells. By shutting down the overactive kinase signals that a tumor depends on, they help slow or stop cancer cells from multiplying.
- How much does Fyarro cost?
- Nobody can tell you what you will pay — your price is set by your insurer's formulary, your deductible and the pharmacy's markup, and none of those are published. What IS published is what the pharmacy paid to acquire it: about $48.61 for 30, per the CMS NADAC survey. Treat that as the floor, not the quote — ask the pharmacist for the cash price as well as your copay, because for cheap generics the cash price often wins.
- Is there a coupon or discount for Fyarro?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Fyarro. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Fyarro?
- Fyarro is marketed by Aadi. You can see Aadi's full profile, rating, and other products on pharmaranks.
- Is Fyarro a brand-name or generic drug?
- Fyarro is a brand-name product with the active ingredient Sirolimus. Lower-cost generic equivalents containing Sirolimus are available — ask your pharmacist.
- Is Fyarro available over the counter?
- No. Fyarro is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Fyarro come in?
- Fyarro is currently marketed as injectable, per the FDA's National Drug Code Directory.
- What class of drug is Fyarro?
- Fyarro is classified as kinase inhibitor, mtor inhibitor immunosuppressant, per the FDA's Established Pharmacologic Class.
- Is Fyarro FDA-registered?
- Fyarro is on record with the U.S. FDA under application number NDA213312. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about SIROLIMUS
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 14,105 reports naming SIROLIMUS — the active ingredient in Fyarro, and the FDA flagged 85% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- pyrexia558 reports
- diarrhoea557 reports
- pneumonia517 reports
- acute kidney injury435 reports
- thrombotic microangiopathy386 reports
- transplant rejection381 reports
- cytomegalovirus infection358 reports
- nausea335 reports
Read these as a signal, not a rate. A report does not mean SIROLIMUS caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
danziten
Nilotinib Tartrate
everolimus
Everolimus
ofev
Nintedanib Esylate
sprycel
Dasatinib
afinitor
Everolimus
calquence
Acalabrutinib
Compare Fyarro head-to-head
More kinase inhibitor drugs
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
fyarro
New